{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T03:51:16Z","timestamp":1795060276228,"version":"4.10.2"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastases traditionally includes omentectomy, even in the absence of visible omental metastases. We sought to determine the rate of occult histologic omental metastasis (OHOM), evaluate morbidity with omentectomy, and examine the rate of omental recurrence among patients undergoing CRS-HIPEC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>All CRS-HIPEC procedures from August 2007 to August 2020 were included in this single-center, retrospective, cohort study. Procedures were divided into those that included greater omentectomy (OM) and those that did not (NOM). The incidence of OHOM was evaluated specifically among the OM group with a grossly normal omentum. Multivariate regression analyses were performed to evaluate return of bowel function, ileus, and morbidity in the OM and NOM groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 683 CRS-HIPEC procedures, 578 (84.6%) included omentectomy and 105 (15.4%) did not. The OM group had higher operative time, blood loss, peritoneal cancer index, number of visceral resections, and length of stay. In the OM group, 72 (12.5%) patients had a grossly normal omentum, and 23 (31.9%) of these had OHOM. Risk-adjusted return of bowel function, ileus, and 60-day complications were no different in the OM and NOM groups. Among 43 patients with residual omentum, 24 (55.8%) recurred, including 9 (20.9%) with omental recurrence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Histologically occult metastasis was present in one-third of patients undergoing omentectomy during CRS-HIPEC. Omentectomy did not increase the rate of overall morbidity, and one-fifth of patients with residual omentum later developed omental recurrence. Thus, omentectomy is warranted in the absence of gross metastases during CRS-HIPEC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-022-12714-7","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T14:03:27Z","timestamp":1666965807000},"page":"768-773","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Is Routine Omentectomy a Necessary Component of Cytoreductive Surgery and HIPEC?"],"prefix":"10.1245","volume":"30","author":[{"given":"Sohini","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen-Huong","family":"Doan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojgan","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jula","family":"Veerapong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Lowy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Baumgartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"12714_CR1","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","volume":"27","author":"TD Yan","year":"2009","unstructured":"Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237\u201342.","journal-title":"J Clin Oncol"},{"key":"12714_CR2","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","volume":"30","author":"TC Chua","year":"2012","unstructured":"Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449\u201356.","journal-title":"J Clin Oncol"},{"key":"12714_CR3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378:230\u201340.","journal-title":"N Engl J Med"},{"key":"12714_CR4","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.18.01688","volume":"37","author":"PE Bonnot","year":"2019","unstructured":"Bonnot PE, Piessen G, Kepenekian V, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol. 2019;37:2028\u201340.","journal-title":"J Clin Oncol"},{"key":"12714_CR5","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:256\u201366.","journal-title":"Lancet Oncol"},{"key":"12714_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/jso.24813","volume":"117","author":"WF Morano","year":"2018","unstructured":"Morano WF, Khalili M, Chi DS, Bowne WB, Esquivel J. Clinical studies in CRS and HIPEC: trials, tribulations, and future directions: a systematic review. J Surg Oncol. 2018;117:245\u201359.","journal-title":"J Surg Oncol"},{"key":"12714_CR7","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jamcollsurg.2013.12.013","volume":"218","author":"EA Levine","year":"2014","unstructured":"Levine EA, Stewart JH, Shen P, Russell GB, Loggie BL, Votanopoulos KI. Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1000 patients. J Am Coll Surg. 2014;218:573\u201385.","journal-title":"J Am Coll Surg"},{"key":"12714_CR8","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1245\/s10434-017-6310-8","volume":"25","author":"M Reghunathan","year":"2018","unstructured":"Reghunathan M, Kelly KJ, Valasek MA, Lowy AM, Baumgartner JM. Histologic predictors of recurrence in mucinous appendiceal tumors with peritoneal dissemination after HIPEC. Ann Surg Oncol. 2018;25:702\u20138.","journal-title":"Ann Surg Oncol"},{"key":"12714_CR9","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.2353\/ajpath.2006.051222","volume":"169","author":"SA Gerber","year":"2006","unstructured":"Gerber SA, Rybalko VY, Bigelow CE, et al. Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. Am J Pathol. 2006;169:1739\u201352.","journal-title":"Am J Pathol"},{"key":"12714_CR10","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/jso.23681","volume":"110","author":"MJ Koppe","year":"2014","unstructured":"Koppe MJ, Nagtegaal ID, de Wilt JH, Ceelen WP. Recent insights into the pathophysiology of omental metastases. J Surg Oncol. 2014;110:670\u20135.","journal-title":"J Surg Oncol"},{"key":"12714_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","volume":"221","author":"PH Sugarbaker","year":"1995","unstructured":"Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29\u201342.","journal-title":"Ann Surg"},{"key":"12714_CR12","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.ejso.2019.11.495","volume":"46","author":"A Bhatt","year":"2020","unstructured":"Bhatt A, Yonemura Y, Mehta S, et al. Target region resection in patients undergoing cytoreductive surgery for peritoneal metastases-Is it necessary in absence of visible disease? Eur J Surg Oncol. 2020;46:582\u20139.","journal-title":"Eur J Surg Oncol"},{"key":"12714_CR13","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1097\/DCR.0000000000001670","volume":"63","author":"I Bonnefoy","year":"2020","unstructured":"Bonnefoy I, Mohamed F, Bonnot PE, et al. Risk of omental metastases in patients undergoing cytoreductive surgery for colorectal peritoneal metastases. Dis Colon Rectum. 2020;63:1251\u20136.","journal-title":"Dis Colon Rectum"},{"key":"12714_CR14","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.ejso.2021.12.026","volume":"48","author":"J Nors","year":"2022","unstructured":"Nors J, Iversen LH, Nielsen K, S\u00f8rensen MM, Verwaal VJ, Funder JA. Peritoneal metastases found in routinely resected specimens after cytoreductive surgery and heated intraperitoneal chemotherapy. Eur J Surg Oncol. 2022;48:795\u2013802.","journal-title":"Eur J Surg Oncol"},{"key":"12714_CR15","doi-asserted-by":"publisher","first-page":"e1425","DOI":"10.1590\/0102-672020180001e1425","volume":"32","author":"LC Barchi","year":"2019","unstructured":"Barchi LC, Ramos M, Dias AR, et al. Total omentectomy in gastric cancer surgery: Is it always necessary? Arq Bras Cir Dig. 2019;32:e1425.","journal-title":"Arq Bras Cir Dig"},{"key":"12714_CR16","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1245\/s10434-014-3985-y","volume":"22","author":"JM Baumgartner","year":"2015","unstructured":"Baumgartner JM, Tobin L, Heavey SF, Kelly KJ, Roeland EJ, Lowy AM. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2015;22:1716\u201321.","journal-title":"Ann Surg Oncol"},{"key":"12714_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/jso.21068","volume":"98","author":"AG Portilla","year":"2008","unstructured":"Portilla AG, Shigeki K, Dario B, Marcello D. The intraoperative staging systems in the management of peritoneal surface malignancy. J Surg Oncol. 2008;98:228\u201331.","journal-title":"J Surg Oncol"},{"issue":"Suppl","key":"12714_CR18","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1007\/s002800051093","volume":"43","author":"PH Sugarbaker","year":"1999","unstructured":"Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol. 1999;43(Suppl):S15\u201325.","journal-title":"Cancer Chemother Pharmacol"},{"key":"12714_CR19","doi-asserted-by":"publisher","first-page":"4908","DOI":"10.1245\/s10434-020-08535-1","volume":"27","author":"A Nikiforchin","year":"2020","unstructured":"Nikiforchin A, King MC, Baron E, et al. Impact of mucin cellularity and distribution on survival in newly diagnosed patients with low-grade appendiceal mucinous neoplasm treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2020;27:4908\u201317.","journal-title":"Ann Surg Oncol"},{"key":"12714_CR20","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ejso.2020.10.020","volume":"47","author":"T Evans","year":"2021","unstructured":"Evans T, Aziz O, Chakrabarty B, et al. Long-term outcomes for patients with peritoneal acellular mucinosis secondary to low grade appendiceal mucinous neoplasms. Eur J Surg Oncol. 2021;47:188\u201393.","journal-title":"Eur J Surg Oncol"},{"key":"12714_CR21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ejso.2010.12.005","volume":"37","author":"DJ Evers","year":"2011","unstructured":"Evers DJ, Smeenk RM, Bottenberg PD, van Werkhoven ED, Boot H, Verwaal VJ. Effect of preservation of the right gastro-epiploic artery on delayed gastric emptying after cytoreductive surgery and HIPEC: a randomized clinical trial. Eur J Surg Oncol. 2011;37:162\u20137.","journal-title":"Eur J Surg Oncol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12714-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-022-12714-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12714-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T14:05:57Z","timestamp":1672668357000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-022-12714-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["12714"],"URL":"https:\/\/doi.org\/10.1245\/s10434-022-12714-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,28]]},"assertion":[{"value":"6 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}